Hepatic encephalopathy market to grow at 1.2% CAGR through 2036, driven by new therapies and rising disease cases

The hepatic encephalopathy market is projected to grow steadily at a 1.2% CAGR through 2036, fueled by increasing cases of chronic liver diseases and cirrhosis globally. Advances in early diagnosis and the introduction of new therapies like VE303, YAQ007, and GR3027 are expected to transform treatment options and expand the market. The U.S. leads the market with 60% share and about 210,000 cases in 2025, with numbers expected to rise. Emerging drugs aim to address unmet needs, potentially improving patient outcomes and reshaping the market landscape.